EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant Recipients

Sonsoles Salto-Alejandre iD, Willa Cochran, Zishan Siddiqui iD, Julie Langlee iD, Lauren Boyer, Kristin Freed, Sophia Purekal, Ishaan Gupta iD, Mary Grace Bowring iD, Daniel C Brennan iD, William Werbel iD, Robin K Avery iD

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.14405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Sonsoles Salto-Alejandre und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Johns Hopkins University, Baltimore, USA. Hauptthemen laut MEDLINE: Organ Transplantation, COVID-19, Transplant Recipients, COVID-19 Drug Treatment. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, Fulbright Grant 2022-2023 to Sonsoles Salto-Alejandre, NHLBI to Mary Grace Bowring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Outcomes after bebtelovimab treatment for COVID‐19 were favorable for most but not all solid organ transplant recipients (SOTRs) during the era of Omicron BA.2 to BA.5, but effects of timing of bebtelovimab administration on these outcomes are unknown. We sought to compare outcomes of SOTR who received early bebtelovimab (“EBT”, given ≤ 2 days from diagnosis) versus late bebtelovimab (“LBT”, given between Days 3 and 7), versus no bebtelovimab (NBT).

Methods

This was a retrospective cohort study of SOTRs with mild‐to‐moderate COVID‐19, with endpoint of 30‐day COVID‐19‐related hospitalization. Multivariable logistic regression was performed to determine variables associated with receiving EBT, and to assess impact of EBT on hospitalization. A propensity score (PS) was calculated for EBT versus NBT.

Results

Of 297 SOTRs, 162 (58.1%) received EBT, 46 (16.5%) LBT, and 71 (25.4%) NBT. Early bebtelovimab treatment was associated with a lower risk of 30‐day COVID‐19‐related hospitalization compared to NBT (OR, 0.112 [95% CI, 0.018–0.686]; p = 0.018). There was no significant difference in hospitalization risk between LBT and NBT, suggesting that delayed administration may not confer additional benefits over no treatment.

Conclusions

Early bebtelovimab treatment in outpatient SOTRs was associated with a lower risk of hospitalization compared to no treatment, while late administration did not show a significant advantage over no treatment. Although bebtelovimab is no longer authorized, these findings suggest that the timing of COVID therapies for SOTRs may be important to optimize outcomes. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Organ TransplantationCOVID-19Transplant RecipientsCOVID-19 Drug TreatmentHumansMaleRetrospective StudiesFemaleMiddle AgedSARS-CoV-2AgedAdultHospitalizationTreatment OutcomeTime Factors

Stichwörter der Autor:innen

COVID‐19COVID‐19 treatmentOmicronSARS‐CoV‐2bebtelovimabhospitalizationsolid organ transplant

Autor:innen und Institutionen

  • Division of Infectious Diseases, Johns Hopkins University, Baltimore, USA.
  • Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, CIBER de Enfermedades Infecciosas, Instit…
  • Comprehensive Transplant Center, Baltimore, USA.
  • School of Medicine, Johns Hopkins University, Baltimore, USA.

ORCID-Profile: Sonsoles Salto-Alejandre, Zishan Siddiqui, Julie Langlee, Ishaan Gupta, Mary Grace Bowring, Daniel C Brennan, William Werbel, Robin K Avery

Förderung

  • NHLBI NIH HHS
  • Fulbright Grant 2022-2023 to Sonsoles Salto-Alejandre
  • NHLBI to Mary Grace Bowring
  • IMFAHE-University Excellence Fellowship 2021 to Sonsoles Salto-Alejandre

Zitieren

APA

Salto-Alejandre, S., Cochran, W., Siddiqui, Z., Langlee, J., Boyer, L., Freed, K., Purekal, S., Gupta, I., Bowring, M. G., Brennan, D. C., Werbel, W., & Avery, R. K. (2025). Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14405

Vancouver

Salto-Alejandre S, Cochran W, Siddiqui Z, Langlee J, Boyer L, Freed K, et al. Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant Recipients. Transplant Infectious Disease. 2025. doi:10.1111/tid.14405

BibTeX
@article{SaltoAlejandre2025,
  author = {Salto-Alejandre, Sonsoles and Cochran, Willa and Siddiqui, Zishan and Langlee, Julie and Boyer, Lauren and Freed, Kristin and Purekal, Sophia and Gupta, Ishaan and Bowring, Mary Grace and Brennan, Daniel C and Werbel, William and Avery, Robin K},
  title = {Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant Recipients},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.14405}
}
Kostenlos starten →